| 18F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate C Sachpekidis, EK Mai, H Goldschmidt, J Hillengass, D Hose, L Pan, ... Clinical nuclear medicine 40 (6), e300-e307, 2015 | 46 | 2015 |
| A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, MS Raab, M Hillengass, ... Haematologica 100 (6), 818, 2015 | 57 | 2015 |
| A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma-an Analysis from Five GMMG and HOVON Multicenter Phase … EK Mai, T Hielscher, U Bertsch, J Schlenzka, HJ Salwender, HM Lokhorst, ... Blood 130, 2016, 2017 | | 2017 |
| A systematic classification of death causes in multiple myeloma EK Mai, EM Haas, S Lücke, M Löpprich, C Kunz, M Pritsch, ... Blood cancer journal 8 (3), 30, 2018 | 38 | 2018 |
| Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial KC Weisel, C Scheid, M Zago, B Besemer, EK Mai, M Haenel, J Duerig, ... Blood Cancer Journal 9 (4), 45, 2019 | 11 | 2019 |
| Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG … H Goldschmidt, EK Mai, E Nievergall, R Fenk, U Bertsch, D Tichy, ... Blood 138, 463, 2021 | 31 | 2021 |
| Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG … H Goldschmidt, EK Mai, U Bertsch, R Fenk, E Nievergall, D Tichy, ... The Lancet Haematology 9 (11), e810-e821, 2022 | 64 | 2022 |
| Analysis of Long-Term Survival in Multiple Myeloma Patients after First-Line Autologous Stem Cell Transplantation: Impact of Clinical Risk Factors and Duration of Response N Lehners, N Becker, A Benner, M Pritsch, EK Mai, J Hillengass, ... Blood 128 (22), 4649, 2016 | | 2016 |
| Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response N Lehners, N Becker, A Benner, M Pritsch, M Löpprich, EK Mai, ... Cancer medicine 7 (2), 307-316, 2018 | 51 | 2018 |
| Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ... The Journal of clinical investigation 122 (6), 1991-2005, 2012 | 508 | 2012 |
| Angiopoietin-2 is critical for cytokine-induced vascular leakage AV Benest, K Kruse, S Savant, M Thomas, AM Laib, EK Loos, U Fiedler, ... PloS one 8 (8), e70459, 2013 | 200 | 2013 |
| Application of 18F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities C Sachpekidis, J Mosebach, MT Freitag, T Wilhelm, EK Mai, ... American journal of nuclear medicine and molecular imaging 5 (5), 479, 2015 | 77 | 2015 |
| Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma C Sachpekidis, O Enqvist, J Ulén, A Kopp-Schneider, L Pan, EK Mai, ... European Journal of Nuclear Medicine and Molecular Imaging, 1-15, 2024 | 2 | 2024 |
| Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma EK Mai, J Kloth, M Merz, S Shah, M Hillengaß, B Wagner, D Hose, ... | | 2016 |
| Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumor mass and biology EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, M Hillengass, B Wagner, ... Clinical Lymphoma, Myeloma and Leukemia 15, e98, 2015 | | 2015 |
| Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, M Hillengass, B Wagner, ... European radiology 26, 3939-3948, 2016 | 48 | 2016 |
| Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma M Merz, T Hielscher, A Seckinger, D Hose, EK Mai, MS Raab, ... American journal of hematology 91 (11), E473-E477, 2016 | 42 | 2016 |
| Bone marrow immune signatures in multiple myeloma are linked to tumor heterogeneity and treatment outcome S Steiger, R Lutz, N Prokoph, S Palit, SM Tirier, P Reichert, A Baumann, ... Blood 140 (Supplement 1), 2083-2085, 2022 | 4 | 2022 |
| Bone marrow plasma cell infiltration rate is higher in multiple myeloma patients with pathological 18F-FDG PET/CT than in patients with normal scans C Sachpekidis, EK Mai, J Hillengass, H Goldschmidt, U Haberkorn, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 42, S694-S694, 2015 | | 2015 |
| Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial H Goldschmidt, HM Lokhorst, EK Mai, B van der Holt, IW Blau, ... Leukemia 32 (2), 383-390, 2018 | 218 | 2018 |
